<DOC>
	<DOCNO>NCT00002243</DOCNO>
	<brief_summary>The purpose study test safety effectiveness new non-nucleoside reverse transcriptase inhibitor ( NNRTI ) , ( + ) -calanolide A , HIV-positive patient never receive anti-HIV treatment .</brief_summary>
	<brief_title>A Study Evaluate Safety Effectiveness New Non-Nucleoside Reverse Transcriptase Inhibitor ( NNRTI ) , ( + ) -Calanolide A , HIV-Positive Patients Who Have Never Received Anti-HIV Treatment</brief_title>
	<detailed_description>Patients randomize 2 cohort , Cohort 2 receive high dosage Cohort 1 . Patients cohort receive either ( + ) -calanolide A placebo 14 day , follow 14-day follow-up period . Following study treatment , patient may elect receive open-label , 6-month course anti-HIV drug select administer care patient 's physician .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<mesh_term>Calanolide A</mesh_term>
	<criteria>Inclusion Criteria You may eligible study : Are HIVpositive . Have CD4 count least 250 cells/mm3 . Have HIV count ( viral load ) least 5,000 copies/ml . Are least 18 year old . Exclusion Criteria You eligible study : Have receive prescription nonprescription medication within 14 day study entry , need take medication study . Have ever receive antiHIV medication . Test positive hepatitis B . Have receive blood ( red blood cell ) transfusion within 3 month prior study entry . Have severe diarrhea . Have severe heart , liver , kidney , neurological ( brain spinal cord ) disease . Have hemophilia another blood disorder . Have receive certain medication vaccine within 30 day prior study entry . Have receive chemotherapy radiation within 16 day prior study entry , need either study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2000</verification_date>
	<keyword>Anti-HIV Agents</keyword>
</DOC>